To further prove that MATE1 has an important role in regulating imatinib sensitivity in CML patients, we analyzed the transporter profile of total BM samples obtained from CML patients by qRT-PCR and correlated the expression levels with the major molecular response to imatinib treatment (Figures 2c and d). Here, SLC47A1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.